Skip to search formSkip to main contentSkip to account menu

birinapant

Known as: Propanamide, N,N'-[(6,6'-difluoro[2,2'-bi-1H-indole]-3,3'-diyl)bis[methylene[(2R,4S)-4-hydroxy-2,1-pyrrolidinediyl][(1S)-1-ethyl-2-oxo-2,1-ethanediyl]]]bis[2-(methylamino)-,(2S,2'S)- 
A synthetic small molecule that is both a peptidomimetic of second mitochondrial-derived activator of caspases (SMAC) and inhibitor of IAP (Inhibitor… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

DipeptidesIndoles
NCIt Antineoplastic Agent Terminology

Narrower (1)

TL32711

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
SMAC Mimetics Induce Autophagy-Dependent Apoptosis of HIV-1-Infected Resting Memory CD4+ T Cells.
Highly Cited
2016
Highly Cited
2016
The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia
The combination of a SMAC mimetic and a caspase inhibitor kills AML cells by inducing necroptosis. Giving leukemia a SMAC Second… 
Highly Cited
2016
Highly Cited
2016
Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.
Highly Cited
2016
Highly Cited
2016
SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.
Comparison of tumors from The Cancer Genome Atlas (TCGA) reveals that head and neck squamous cell carcinomas (HNSCC) harbor the… 
2015
2015
Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC
Head and neck squamous cell carcinoma (HNSCC) cells are resistant to cell death induced by tumor necrosis factor ligands such as… 
Highly Cited
2014
Highly Cited
2014
Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft Models
The acquisition of apoptosis resistance is a fundamental event in cancer development. Among the mechanisms used by cancer cells… 
Highly Cited
2014
Highly Cited
2014
Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies.
Birinapant (1) is a second-generation bivalent antagonist of IAP proteins that is currently undergoing clinical development for… 
Highly Cited
2014
Highly Cited
2014
Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.
BACKGROUND Acute myeloid leukemia (AML) therapy has limited long-term efficacy because patients frequently develop disease… 
Highly Cited
2013
Highly Cited
2013
The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells
Purpose: Inhibitor of apoptosis proteins (IAP) promote cancer cell survival and confer resistance to therapy. We report on the… 
Highly Cited
2012
Highly Cited
2012
Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism
X-linked inhibitor of apoptosis protein (XIAP), the most potent mammalian caspase inhibitor, has been associated with acquired… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)